Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic MX-ICP Lung Cancer Analysis Panel

Transgenomic has launched multiplexed ICE COLD PCR (MX-ICP) non-small cell lung cancer analysis panel. The panel covers the key actionable mutations that are relevant to the targeted treatment of NSCLC. It tests for the relevant mutations in important actionable genes, including EGFR exons 18 - 21, KRAS exons 2 and 3, BRAF 15 (V600E) and PIK3CA exons 9 and 20. Multiplexed ICE COLD - PCR achieves its ultra-high sensitivity through selective amplification of mutant DNA. The result is up to a 500-fold increase in sensitivity in identifying mutations with the most precise sequence alteration detection rates available — down to 0.01 percent from as little as a 4 ml plasma sample, said Transgenomic in a statement. It is available for clinical diagnostic use through the company's CLIA laboratory.